CN202061251U - Implanted intelligent blood pressure regulating device - Google Patents
Implanted intelligent blood pressure regulating device Download PDFInfo
- Publication number
- CN202061251U CN202061251U CN2011200661858U CN201120066185U CN202061251U CN 202061251 U CN202061251 U CN 202061251U CN 2011200661858 U CN2011200661858 U CN 2011200661858U CN 201120066185 U CN201120066185 U CN 201120066185U CN 202061251 U CN202061251 U CN 202061251U
- Authority
- CN
- China
- Prior art keywords
- blood pressure
- regulating device
- optical fiber
- implanted
- pressure regulating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Abstract
The utility model discloses an implanted intelligent blood pressure regulating device. The implanted intelligent blood pressure regulating device includes an external program control device with parameters settable and an internal regulating device for regulating the blood pressure. The internal regulating device includes an internal controller, a pulse generator and an electrode extending into the vessel wall to stimulate the carotid sinus. The external program control device emits program control radiofrequency signals to the internal regulating device according to the parameters set by a user. The internal regulating device is powered by an inner power supply. The internal regulating device also includes an optical fiber blood pressure transducer for detecting the blood pressure and sending the blood pressure signals to the internal controller. In the utility model, the volume of the implanted intelligent blood pressure regulating device is small, the implanted intelligent blood pressure regulating device can monitor the internal blood pressure condition of a patient in real time, adjust the stimulation mode and stimulation parameters according to the dynamic change of the blood pressure, and regulate different adjusting stimulation modes and stimulation parameters according to the concrete condition of a patient.
Description
Technical field
This utility model relates to a kind of blood pressure regulating device, particularly a kind of implanted intelligence blood pressure regulating device.
Background technology
Hypertension is one of the most common cardiovascular disease that prevalence height, complication are many, the fatality rate that disables is high.Statistics showed in 2000: in the world wide, adult's hypertension prevalence is 26.4%, estimates that total prevalence rate in 2025 will reach 29.2%; 2002, China showed the hypertension investigation of 14 provinces and cities: adult's hypertension prevalence is 33.95%; The apoplexy of about 50%-60% is relevant with hypertension with the generation of the myocardial infarction of 40%-50%, and hyperpietic's controlling of blood pressure is bad, will cause the heart, brain, kidney and peripheral blood vessel infringement also finally to cause the nonfunction of corresponding organ; China has 1,500,000 people to die from hypertension every year approximately; Therefore, hypertension has become one of great public health problem in the global range of serious threat human health.
Hypertension is a kind of independently chronic disease, is again the important risk factor that causes apoplexy, myocardial infarction, heart failure and chronic kidney disease.Blood pressure is from 110/75mmHg, and the danger that the meeting of rising of its level drives cardiovascular disease increases.The apoplexy of 50%-60% takes place relevant with hypertension with the myocardial infarction of 40%-50%.As hypertensive common complication, apoplexy and heart disease have become the current major disease that threatens China's residents ' health.According to epidemiologic data, estimation China annual New Development apoplexy 2,000,000 people, New Development myocardial infarction 500,000 people die from cardiovascular and cerebrovascular disease 3,000,000 people, annual main cardiovascular diseases's direct medical cost reaches 1,300 hundred million yuan, wherein is used for hypertensive medical care expenses and reaches 36,600,000,000 yuan.Clinical research shows, on average reduces systolic pressure 10mmHg, diastolic pressure 5mmHg, the apoplexy decline 40%-50% that causes danger, and the coronary heart disease decline 15%-20% that causes danger, heart failure is caused danger and is reduced 50%.Reduce hyperpietic's blood pressure level, the prevention cardiovascular and cerebrovascular disease is had a very important role.
At present, treating hypertensive main method has: two kinds of Drug therapy and non-drug therapies.The former is present the most frequently used effective ways, but has accumulative total expense height, adverse effect is difficult to avoid and take medicine throughout one's life to patient's life shortcoming such as make troubles, so patient's drug compliance difference and treatment rate are low; The latter comprise change lifestyles, several methods such as aerobatic exercise, psychological intervention, gene therapy and electricity irritation carotid sinus nerve, but all can not reach the ideal role of safe, effective and steady blood pressure lowering.
The central nervous system blood pressure regulating reflection that autonomic nervous system participates in of unifying is the main mechanism that human blood-pressure is transferred.When hypertension, tractive is positioned at sino-carotid pressure receptor, by orthosympathetic centripetal fiber information is reached vasomotor center, and orthosympathetic activeness is reduced, and orthosympathetic vasoconstrictor fiber is suppressed, thereby blood pressure is reduced; Otherwise, when blood pressure reduces,, sympathetic irritability is strengthened also by this reflection approach, blood pressure is recovered.Above-mentioned blood pressure regulating mechanism is to be inspired by fluctuation of blood pressure, realizes that by carotid sinus baroreceptor-carotid sinus nerve-central nervous system-orthosympathetic reflection approach this reflection is called as depressor reflex.Early stage research is thought: when blood pressure departs from normal range constantly, the horizontal reset of pressure receptor level and/or nervus centralis, reset is meant the phenomenon in the pressure experience reflection function curve right shift of hyperpietic or animal, also is that the finger pressure ergoreceptor carries out work on normal high blood pressure level.Research is in recent years thought: depressor reflex has important feedback regulation effect in the chronic hypertension generating process; The pressure receptor reset may not be long-term hypertensive result, but one of major reason that hypertension takes place.So abroad some scholars attempt by intervening the purpose of depressor reflex realization blood pressure lowering.
Treat hypertensive present Research and deficiency by intervening depressor reflex: as far back as 1958, people such as Warner just discovery carried out can significantly the bring high blood pressure down mean arterial pressure level of normal dogs of stimulus of direct current to carotid sinus nerve.People such as Carlsten implement in the head and neck surgical procedures 5 routine patients, carotid sinus nerve is carried out electricity irritation after, observe blood pressure, heart rate descends rapidly, stops electricity irritation, gets back to baseline values again rapidly.1967, people such as Schwartz observed 5 to 36 months after 8 routine obstinate hypertension (blood pressure is in the 190-300/110-220mmHg level) are implanted carotid sinus nerve stimulator, found that the blood pressure 48/42mmHg that on average descends, wherein 6 routine patients have stopped Drug therapy.1980, the identical method of employings such as Peters also realized the purpose of steady reduction hyperpietic blood pressure, and in continuous 12 years observation, this treatment measure is still effective.But the common deficiency that exists of these researchs is: employed electric pulse generator volume is huger, battery is shorter service life, electrode material and implanted prosthetics fall behind, cause carotid sinus surrounding tissue and nerve stimulation easily, cause various clinical symptoms such as patient's cervical pain, dysphonia, the most fatal deficiency is that at that time Computer Processing is backward in technique, can not be in real time come the blood pressure regulation level to return to normal range, therefore cause hypotension and decreased heart rate situation to take place easily according to the variation of patient's blood pressure.Therefore, in the time surplus in the of 20 year subsequently, this technology almost stays cool.Up to 2005, U.S. CVRx company developed the novel carotid sinus stimulation device of a kind of Rheos by name, and the clinical trial of participating in by one 16 routine patient confirms that this equipment can reduce the blood pressure of obstinate hypertension within the specific limits.The development of U.S. CVRx company
(patent No. is respectively: 6522926,6616624 and 6850801) in USPO's registration in therapy equipment.But also there are a lot of problems in this therapy equipment: 1, this system does not have real-time blood pressure perceptive function, can only provide electric pulse stimulation regularly, can not adjust stimulus modelity and stimulus parameter in real time at the dynamic change of blood pressure, therefore can not realize demand hyperpietic's individualized treatment; 2, there are two collar tremulous pulse hole stimulating electrodes and the pulse generator that volume is bigger in this system, causes that the implant surgery wound is big, operation is complicated, needs Anesthesia Department, vascular surgery, neurosurgery and intracardiac section specialist to finish jointly; Though 3, this device also has supporting vitro program controlled instrument, but it can only program control simply two stimulus parameters, be stimulation voltage and stimulus frequency,, therefore can not satisfy the needs of blood pressure regulating multiparameter individuation not to the programmable function of blood pressure perception and treatment pattern; 4, can only solve by the pulse generator that more renews of performing the operation once more behind the battery depletion of this system, increase patient's misery and expense.
Although there are a lot of deficiencies in above-mentioned research and demand improved problem urgently, the theoretical basis and the implementation method of this treatment measure get the nod.Compare with other non-drug therapy with Drug therapy, the blood pressure level that reduces the hyperpietic by intervention depressor reflex is a hypertension non-drug therapy that prospect is boundless, China still is in space state in this research field at present, and all there is tangible deficiency in external existing similar research.
The utility model content
The purpose of this utility model provides a kind of hypertensive implanted intelligence blood pressure regulating device that is used for the treatment of, under the prerequisite of dynamic perception human body artery blood pressure, by being carried out intelligence, the depressor nerve impulsion of depressor reflex arc regulates, make the blood pressure lowering instruction of blood pressure maincenter granting safety appropriateness, realize lasting, steady, individuation blood pressure lowering treatment hypertension.
The implanted intelligence blood pressure regulating device that this utility model provides, but comprise setup parameter vitro program controlled instrument and can be by adjusting device in the body that is used for blood pressure regulation of described vitro program controlled instrument control, adjusting device comprises body internal controller, pulse generator and can put in the electrode to carotid sinus stimulation of being used for of blood vessel wall in the described body, and described vitro program controlled instrument sends signal according to parameter of user to described body internal controller; Adjusting device is powered by an internal electric source in the described body, and wherein: adjusting device also comprises an optical fiber pressure transducer that is used to detect blood pressure and the signal of described blood pressure is flowed to described body internal controller in the described body.
Above-mentioned body internal controller receives the signal of the blood pressure of the signal of described vitro program controlled instrument and/or described optical fiber pressure transducer, and regulate and control described pulse generator in view of the above and send electric impulse signal to described electrode, thereby described electrode receives described electric impulse signal and sends corresponding stimulating current in view of the above and activate carotid artery baroreflex blood pressure regulation.
The signal that above-mentioned vitro program controlled instrument sends is preferably program control radiofrequency signal.
Above-mentioned optical fiber pressure transducer has that size is enough little, high sensitivity, high frequency response, high reliability, excellent biological compatibility, stronger capacity of resisting disturbance, conveniently install and fix advantage.
Further, above-mentioned optical fiber pressure transducer is fixed on the described electrode, also is integrated design, and preferably the center of above-mentioned electrode is provided with micropore, and described optical fiber pressure transducer is plugged in the described micropore.
Above-mentioned optical fiber pressure transducer can comprise:
Be used to send radiative led light source;
The flexible sheet of elastic displacement can take place the side pressure effect of described blood vessel wall because of blood;
Receive described emission light and described emission light is sent to first group of optical fiber of described flexible sheet;
Catoptrical second group of optical fiber that reception is formed through described flexible sheet reflection by described emission light;
With the catoptrical photodetector that receives described second group of optical fiber transmission.
Preferably: the distance of above-mentioned first group of optical fiber and described second group of optical fiber and described flexible sheet is 30um; The multimode optical fibre that described first group of optical fiber and described second group of optical fiber are 50um by 80 diameters is altogether formed.
Further, above-mentioned optical fiber pressure transducer is to send described photodetector measured signal to described body internal controller by transmitter.
The volume of above-mentioned pulse generator is less than 25 cubic centimetres, the voltage-regulation scope is 1.0-8.0V, the controlled resolution of voltage is 0.5V, frequency-tuning range is 10-100Hz, the controlled resolution of frequency is 1Hz, the pulse width modulation scope is 0.1-1ms, and the controlled resolution of pulse width is 0.02ms.
Above-mentioned pulse generator can comprise the voltage AM circuit of regulating described electric impulse signal amplitude and the electrode drive circuit that is used to regulate the frequency and the pulsewidth of described electric impulse signal and drives described electrode work.
Further, above-mentioned pulse generator sends described electrode to after by the CMOS amplifying circuit described electric impulse signal being amplified.
Above-mentioned internal electric source is a charging device in the body, and described implanted intelligence blood pressure regulating device also comprises an external electric supply installation in external charging device charging in described body.
Above-mentioned vitro program controlled instrument can be specifically be arranged on intravital communication device by one and transmits program control radiofrequency signal to described body internal controller.
Send the electric impulse signal of different stimulated amplitude, stimulus frequency and pulsewidth by above-mentioned body internal controller may command pulse generator, thereby reach the purpose that to carry out different blood pressure regulating at Different Individual.
Utility model people of the present utility model fully utilizes hypertension animal model and makes up, the neural blood vessel fine dissection, the neuroregulation mechanism of depressor reflex, pressure perception and sensor-based system, Wicresoft's intervene operation technology, computer program control technology and realize means such as the mutual and battery powered of information bidirectional by radio-frequency communication and radio frequency powered technology, develop implanted intelligence blood pressure regulating device of the present utility model, animal experiment by strictness is to the safety of whole system, effectiveness and stability are estimated, and finally obtain safety, effectively, intelligent, can the intelligent blood pressure regulating device of this utility model implanted vitro program controlled and charging.
The utlity model has following advantage:
1, has the optical fiber pressure transducer that to monitor blood pressure situation in patient's body in real time, can adjust stimulus modelity and stimulus parameter in real time, therefore can realize demand hyperpietic's individualized treatment at the dynamic change of blood pressure;
2, the volume of pulse generator is enough little, is easy to carry out install in the body hands art;
3, have according to the concrete condition control different adjustment stimulus modelity of conditions of patients and the vitro program controlled instrument and the body internal controller of stimulus parameter;
4, the pulse generator that has each parameters such as may command stimulation amplitude, stimulus frequency and stimulation pulsewidth that are complementary with the body internal controller.
5, the external electric supply installation in this utility model solves the battery depletion problem of this utility model device, implanted that assurance implants intelligence blood pressure regulating device can continuous firing, utilizes the radio frequency powered technology to finish charging to in-body power source by external electric supply installation to charging device in the body.
6, designed especially by optical fiber pressure transducer and electrode and constituted the integrated electrode conduit.
Description of drawings
Figure 1A is the module diagram of the implanted intelligence blood pressure regulating device of this utility model embodiment 1.
Figure 1B is the implanted intelligence blood pressure regulating device workflow diagram of this utility model embodiment 1.
Fig. 2 is the structural representation of optical fiber pressure transducer of the implanted intelligence blood pressure regulating device of this utility model embodiment 1.
Fig. 3 is the optical fiber pressure transducer of this utility model embodiment 1 and the modular construction assembling sketch map of electrode formation.
Fig. 4 is the voltage AM circuit and the electrode drive circuit of the pulse generator among this utility model embodiment 1.
The specific embodiment
The utility model is described in further detail below in conjunction with specific embodiment, but this utility model is not limited to following examples.
Shown in Figure 1A and Figure 1B, implanted intelligence blood pressure regulating device of the present utility model comprises internal electric source 1, external electric supply installation 2, can set the vitro program controlled instrument 3 and the interior adjusting device of the body that is used for blood pressure regulation of control parameter, adjusting device can be by vitro program controlled instrument 3 controls in the body.Adjusting device is by above-mentioned internal electric source 1 power supply in this body.Above-mentioned internal electric source is a charging device in the body, external electric supply installation 2 can external in body charging device 1 charging to keep the continuous firing of adjusting device 1 in the body.
Adjusting device comprises body internal controller 41, pulse generator 42 and can put in the electrode 43 and the optical fiber pressure transducer 44 to carotid sinus stimulation of being used for of blood vessel wall in the body, and this optical fiber pressure transducer 44 can be used for detecting blood pressure and the signal of this blood pressure is carried donor internal controller 41.Vitro program controlled instrument 3 can send program control radiofrequency signal to body internal controller 41 according to parameter of user; The signal of the program control radiofrequency signal of body internal controller 41 reception vitro program controlled instruments 3 and/or the blood pressure of optical fiber pressure transducer 42, and control pulse generator 42 sends electric impulse signal to electrode 43 in view of the above, thereby electrode 43 receives above-mentioned electric impulse signal and sends corresponding stimulating current in view of the above and activate carotid artery baroreflex blood pressure regulation.Above-mentioned vitro program controlled instrument 3 specifically is arranged on intravital communication device 5 by one and transmits program control radiofrequency signal to body internal controller 41.The radiofrequency signal that vitro program controlled instrument 3 also can be passed back by these communication device 5 acceptor internal controller 41 is to realize two-way information interaction.Vitro program controlled instrument 3 can be according to the needs of the treatment of individuation blood pressure lowering clinically, monitor the duty and the ruuning situation of body internal controller 41 in real time, this vitro program controlled instrument 3 is complementary with body internal controller 41, and vitro program controlled instrument 3 is realized and the operation of body internal controller 41 two-way information interactions by radio-frequency communication.
As shown in Figure 2, optical fiber pressure transducer 44 comprises: be used to send radiative led light source 441; The flexible sheet 442 of elastic displacement can take place the side pressure effect of blood vessel wall because of blood; Receive above-mentioned emission light and will launch first group of optical fiber 443 that light sends flexible sheet 442 to; Catoptrical second group of optical fiber 444 that reception is formed through flexible sheet 442 reflections by above-mentioned emission light; With the catoptrical photodetector 445 that receives above-mentioned second group of optical fiber, 444 transmission.Optical fiber pressure transducer 44 transmits donor internal controller 41 by transmitter 45 with photodetector 445 measured signals in the optical fiber pressure transducer 44.First group of optical fiber 443 and second group of optical fiber 444 are 30um with flexible sheet 442 apart from d; The multimode optical fibre that first group of optical fiber and second group of optical fiber are 50um by 80 diameters is altogether formed.It is 0.125mm that optical fiber pressure transducer 44 can adopt end diameter, measuring range ± 300mm Hg, precision ± 8mm Hg, resolution 0.4mm Hg, operating temperature 10-50 ℃ medical optical fiber pressure transducer.
As shown in Figure 3, for blood pressure measuring ability and electric pulse stimulation function with this utility model device gather together, designed especially by optical fiber pressure transducer 44 and electrode 43 to constitute the integrated electrode conduit.This integrated electrode guide-tube structure is: the center of electrode 43 is provided with micropore, and optical fiber pressure transducer 44 is plugged in this micropore.The end of electrode is provided with the electrode wires 46 that is used for the transmission pulse signal of telecommunication.Electrode in the present embodiment can be titanium memorial alloy electrode.Optical fiber pressure transducer 44 and electrode 43 are when mounted, can wear the hole of the about 2-3mm of a diameter earlier at the wall of blood vessel 47 by percutaneous vascular puncture technology, utilize carrier closed electrode to be delivered to the position, hole of blood vessel wall, withdraw from carrier then, the hole that the front-end and back-end electrode opens blood vessel wall blocks.Then pressure transducer is delivered to position suitable in the lumen of vessels by the electrode centers micropore.
The volume of pulse generator 42 is 25 cubic centimetres, and weight is 70g, volume: length * wide * height is 60mm * 60mm * 8mm; The voltage-regulation scope of this pulse generator 42 is 1.0-8.0V, the controlled resolution of voltage is 0.5V, and frequency-tuning range is 10-100Hz, and the controlled resolution of frequency is 1Hz, the pulse width modulation scope is 0.1-1ms, and the controlled resolution of pulse width is 0.02ms.This pulse generator 42 comprises the voltage AM circuit of regulating above-mentioned electric impulse signal amplitude and the electrode drive circuit that is used to regulate the frequency and the pulsewidth of above-mentioned electric impulse signal and drives above-mentioned electrode work.Above-mentioned pulse generator sends electrode to after can above-mentioned electric impulse signal being amplified by the CMOS amplifying circuit.
Body internal controller 41 can be selected the control core of microprocessor MSP430F2132 as system for use, and as shown in Figure 4, this system can adopt the SEPIC topological circuit to finish voltage AM, and promptly the voltage AM circuit of above-mentioned pulse generator is a SEPIC topological circuit.Particularly, voltage AM is that PWM intervalometer A by MSP430F2132 finishes.The dutycycle of regulating metal-oxide-semiconductor V1 by PWM_A is the scalable output voltage.And being PWM intervalometer B by MSP430F2132, the frequency of pulse generator and pulsewidth realize, regulate the metal-oxide-semiconductor of stimulating electrode drive circuit by PWM_B, can finish required frequency of stimulating electrode and pulsewidth, this circuit also is above-mentioned electrode drive circuit.
During this utility model device busy, body internal controller 41 is as central control system, the arteriotony data of its monitoring being gathered by optical fiber pressure transducer 44 transmit donor internal controller 41, body internal controller 41 is relatively calculated the signal of vitro program controlled instrument 3 inputs and the arteriotony data of collection, generate required stimulus signal, send the electric impulse signal control electrode after stimulus signal is handled through pulse generator and produce corresponding stimulating current signal, finish sino-carotid stimulation, bring high blood pressure down thereby regulate.The computational methods that body internal controller 41 is concrete are as follows:
(1) receives the blood pressure signal of optical fiber pressure transducer transmission and the signal of the intervention upper limit that the reception vitro program controlled instrument is set;
(2) compare pressure value and intervention higher limit:
When pressure value when intervening higher limit, the body internal controller maintains the original state;
When pressure value when intervening higher limit, adopt following 1-6 level stimulus modelity to treat:
1 grade: one-sided rudimentary stimulus modelity (one-sided stimulation, voltage 0.0-2.0V, frequency 0-40Hz); 2 grades: one-sided intermediate stimulus modelity (one-sided stimulation, voltage 2.1-4.0V, frequency 41-70Hz); 3 grades: one-sided senior stimulus modelity (one-sided stimulation, voltage 4.1V-6.0V, frequency 71-100Hz); 4 grades: the rudimentary stimulus modelity of bilateral (bilateral stimulation, voltage 0.0-2.0V, frequency 0-40Hz); 5 grades: bilateral middle rank stimulus modelity (bilateral stimulation, voltage 2.1-4.0V, frequency 41-70Hz); 6 grades: the senior stimulus modelity of bilateral (bilateral stimulation, voltage 4.1V-6.0V, frequency 71-100Hz).
Above-mentioned embodiment is one of case study on implementation of utility model, is not to limit practical range of the present utility model with this, so all equivalences of doing according to shape of the present utility model, structure and principle change, all should be encompassed in the protection domain of the present utility model.
Type with noinvasive ambulatory blood pressure monitoring and definite patient's diurnal blood pressure level and fluctuation of blood pressure curve, according to the degree of dependence of vitals such as the hardenability of the degree of each patient's hypertension, time that hypertension continues, peripheral arterial, the heart, brain, kidney to blood pressure level, formulate individuation blood pressure lowering target, formulate blood pressure conciliation pattern and stimulus intensity according to the extent of reaction that patient's blood pressure level paired pulses stimulates.For the hyperpietic's that adapts to different arteriotony levels actual blood pressure lowering requirement, the body internal controller in the native system has following two kinds of blood pressure lowering mode of operations can supply program control selection.
One. steady decompression mode.With initial arteriotony is reference, in the time of setting, progressively brings high blood pressure down with certain steady speed, till pressure value up to standard.For example, certain patient's initial systolic arterial pressure is 180mmHg, be set in the pressure value up to standard of according to the amplitude of decline 10% in per 24 hours systolic arterial pressure being reduced to 130mmHg in 72 hours, its 3 days systolic arterial pressure level and blood pressure lowering amplitude are as shown in table 1 respectively, initial arteriotony 180mmHg, blood pressure lowering 10% in per 24 hours was steadily reduced to systolic arterial pressure about 131mmHg at 72 hours.
The therapeutic outcome of table 1, steady decompression mode
| The 1st day (24h) | The 2nd day (48h) | The 3rd day (72h) | |
| Initial blood pressure (mmHg) | 180 | 162 | 145 |
| Blood pressure lowering amplitude (%) | 10 | 10 | 10 |
| Desired value (mmHg) | 162 | 145 | 131 |
| Drop-out value (mmHg) | 18 | 16.2 | 14.5 |
For the primary hypertension patient of making a definite diagnosis, usually be that the 20%-30% of systolic pressure is a therapeutic goal with the blood pressure range of decrease in the 72h clinically, purpose is to avoid the too fast untoward reaction due to excessive of blood pressure lowering, the value up to standard of blood pressure being reduced to this patient with about 3 days times generally all is very safe, can effectively guarantee accommodation and effective circumfusion of patient's vitals.With steady decompression mode is example, and the concrete operation principle of native system and the selection and the setting up procedure of program control parameter are as follows:
The first step, blood pressure lowering amplitude, pressure value up to standard in program control setting blood pressure lowering time window, unit interval.Setting principle is that high more, the up to standard pressure value of basic blood pressure is low more, and the blood pressure lowering time window should be corresponding long more, and the blood pressure lowering amplitude should correspondingly reduce in the unit interval.Prolong the blood pressure lowering time window and can correspondingly reduce interior blood pressure lowering amplitude of unit interval, reach the purpose of steady blood pressure lowering.
For example, certain patient's basic systolic arterial pressure is 1800mmHg, and pressure value up to standard is 130mmHg.If the blood pressure lowering time window of (72 hours) of selecting 3 days, 10% blood pressure lowering amplitude, 3 blood pressure lowering gradients, the systolic arterial pressure of every day and drop-out value thereof are so:
The 1st day initial decompression: systolic arterial pressure: 180-180mmHg * 10%=162.5mmHg, drop-out value of blood pressure: 180mmHg * 10%=18mmHg.
Transition blood pressure lowering in the 2nd day: systolic arterial pressure; 162-162mmHg * 10%=145mmHg, drop-out value of blood pressure=162mmHg * 10%=16.2mmHg.
Blood pressure lowering up to standard in the 3rd day: systolic arterial pressure; 145-145mmHg * 10%=131.3mmHg, drop-out value of blood pressure=145mmHg * 10%=14.5mmHg.
If this example patient is selected 6 days blood pressure lowering time window, 5% blood pressure lowering amplitude, 6 blood pressure lowering gradients, the systolic arterial pressure of every day and drop-out value thereof are so:
The 1st day initial decompression: systolic arterial pressure: 180-180mmHg * 5%=171mmHg, drop-out value of blood pressure: 180mmHg * 5%=9mmHg.
Transition blood pressure lowering in the 2nd day: systolic arterial pressure: 171-171mmHg * 5%=162.45mmHg, drop-out value of blood pressure=171mmHg * 5%=8.55mmHg.
Transition blood pressure lowering in the 3rd day: systolic arterial pressure: 162.45-162.45mmHg * 50%=154.33mmHg, drop-out value of blood pressure=162.45mmHg * 10%=8.12mmHg.
Transition blood pressure lowering in the 4th day: systolic arterial pressure: 154.33-154.33mmHg * 5%=146.61mmHg, drop-out value of blood pressure: 154.33mmHg * 5%=7.72mmHg.
Transition blood pressure lowering in the 5th day: systolic arterial pressure: 146.61-146.61mmHg * 5%=139.28mmHg, drop-out value of blood pressure=146.61mmHg * 5%=7.33mmHg.
Blood pressure lowering up to standard in the 6th day: systolic arterial pressure: 139.28-139.28mmHg * 5%=132.32mmHg, drop-out value of blood pressure=139.28mmHg * 5%=6.96mmHg.
In second step, measure and program control initial impulse intensity or the rank (24 hours) that the hyperpietic is set.Promptly measure the needed stimulus intensity of elementary therapeutic goal that the hyperpietic reaches systolic arterial pressure decline 10%.160mmHg is an example with this example patient systolic pressure, records that systolic pressure is dropped to the needed stimulus intensity of 160-160mmHg * 10%=144mmHg is 3 grades, and its incentive condition is one-sided carotid sinus stimulation, voltage 5.0V, frequency 85Hz.This i.e. first day running parameter.If the actual artery blood pressure can not reach above-mentioned elementary therapeutic goal, system will adjust stimulus intensity automatically in the scope of last next stimulus intensity, and the blood pressure stabilization that makes first day is near elementary blood pressure desired value.
In the 3rd step, transition stimulus intensity or rank (48 hours) are set automatically.Promptly automatically calculate the systolic arterial pressure antihypertensive effect that to obtain in the first day 10% transition period blood pressure desired value that will reach that descends again.This patient's transition period blood pressure desired value is: 144-144mmHg * 10%=129.6mmHg.According to this calculating desired value, system adjusts stimulus intensity automatically in the scope of last next stimulus intensity, and the blood pressure stabilization that makes second day is near transition period blood pressure desired value.
In the 4th step, stimulus intensity up to standard or rank (72 hours) are set automatically.Promptly calculate the systolic arterial pressure antihypertensive effect continuation decline 10% conventional blood pressure desired value that will reach that second day is obtained automatically.This patient's conventional blood pressure desired value is: 129.6-129.6mmHg * 10%=116.64mmHg.According to this calculating desired value, system adjusts stimulus intensity automatically in the scope of last next stimulus intensity, and the blood pressure stabilization that makes the 3rd day is near pressure value up to standard.
Two. practical decompression mode.With initial arteriotony is reference, in the time of setting, preceding 30% time period reduces to arteriotony in the safety range, rapidly with blood pressure lowering amplitude faster then, progressively bring high blood pressure down with certain steady speed in 70% time period of back, till pressure value up to standard.For example, certain patient's initial systolic arterial pressure is 200mmHg, be set in the value up to standard of in 72 hours systolic arterial pressure being reduced to 150mmHg, its 3 days systolic arterial pressure level and blood pressure lowering amplitude are as shown in table 2 respectively, initial arteriotony 200mmHg, 30% time period of pro-(the 1st 24 hours) is reduced to arteriotony safety range (170mmHg) rapidly with blood pressure lowering amplitude faster (15%); Then, progressively bring high blood pressure down with certain steady speed (5%) in back 70% time period (48 and 72 hours), till pressure value up to standard (153.4mmHg).
The therapeutic effect of table 2, practical decompression mode
| The 1st day (24h) | The 2nd day (48h) | The 3rd day (72h) | |
| Initial blood pressure (mmHg) | 200 | 170 | 161.5 |
| Blood pressure lowering amplitude (%) | 15 | 5 | 5 |
| Desired value (mmHg) | 170 | 161.5 | 153.4 |
| Drop-out value (mmHg) | 30 | 8.5 | 8.1 |
Claims (10)
1. implanted intelligence blood pressure regulating device, but comprise setup parameter vitro program controlled instrument and can be by adjusting device in the body that is used for blood pressure regulation of described vitro program controlled instrument control, adjusting device comprises body internal controller, pulse generator and can put in the electrode to carotid sinus stimulation of being used for of blood vessel wall in the described body, and described vitro program controlled instrument sends signal according to parameter of user to described body internal controller; Adjusting device is powered by an internal electric source in the described body, it is characterized in that: adjusting device also comprises an optical fiber pressure transducer that is used to detect blood pressure and the signal of described blood pressure is flowed to described body internal controller in the described body;
Described body internal controller receives the signal of the blood pressure of the signal of described vitro program controlled instrument and/or described optical fiber pressure transducer, and regulate and control described pulse generator in view of the above and send electric impulse signal to described electrode, thereby described electrode receives described electric impulse signal and sends corresponding stimulating current in view of the above and activate carotid artery baroreflex blood pressure regulation.
2. implanted intelligence blood pressure regulating device according to claim 1, it is characterized in that: the signal that described vitro program controlled instrument sends is program control radiofrequency signal.
3. implanted intelligence blood pressure regulating device according to claim 1 and 2, it is characterized in that: described optical fiber pressure transducer is fixed on the described electrode.
4. implanted intelligence blood pressure regulating device according to claim 1 and 2, it is characterized in that: described optical fiber pressure transducer comprises:
Be used to send radiative led light source;
The flexible sheet of elastic displacement can take place the side pressure effect of described blood vessel wall because of blood;
Receive described emission light and described emission light is sent to first group of optical fiber of described flexible sheet;
Catoptrical second group of optical fiber that reception is formed through described flexible sheet reflection by described emission light;
With the catoptrical photodetector that receives described second group of optical fiber transmission;
The distance of described first group of optical fiber and described second group of optical fiber and described flexible sheet is 30um; The multimode optical fibre that described first group of optical fiber and described second group of optical fiber are 50um by 80 diameters is altogether formed.
5. implanted intelligence blood pressure regulating device according to claim 4, it is characterized in that: described optical fiber pressure transducer sends described photodetector measured signal to described body internal controller by transmitter.
6. implanted intelligence blood pressure regulating device according to claim 1 and 2, it is characterized in that: the volume of described pulse generator is less than 25 cubic centimetres, the voltage-regulation scope is 1.0-8.0V, the controlled resolution of voltage is 0.5V, frequency-tuning range is 10-100Hz, the controlled resolution of frequency is 1Hz, and the pulse width modulation scope is 0.1-1ms, and the controlled resolution of pulse width is 0.02ms.
7. implanted intelligence blood pressure regulating device according to claim 1 and 2, it is characterized in that: described pulse generator comprises the voltage AM circuit of regulating described electric impulse signal amplitude and the electrode drive circuit that is used to regulate the frequency and the pulsewidth of described electric impulse signal and drives described electrode work.
8. implanted intelligence blood pressure regulating device according to claim 1 and 2 is characterized in that: described pulse generator sends described electrode to after by the CMOS amplifying circuit described electric impulse signal being amplified.
9. implanted intelligence blood pressure regulating device according to claim 1 and 2, it is characterized in that: described internal electric source is a charging device in the body, and described implanted intelligence blood pressure regulating device also comprises an external electric supply installation in external charging device charging in described body.
10. implanted intelligence blood pressure regulating device according to claim 1 and 2, it is characterized in that: described vitro program controlled instrument is arranged on intravital communication device by one and transmits program control radiofrequency signal to described body internal controller.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011200661858U CN202061251U (en) | 2011-03-15 | 2011-03-15 | Implanted intelligent blood pressure regulating device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011200661858U CN202061251U (en) | 2011-03-15 | 2011-03-15 | Implanted intelligent blood pressure regulating device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN202061251U true CN202061251U (en) | 2011-12-07 |
Family
ID=45055134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011200661858U Expired - Fee Related CN202061251U (en) | 2011-03-15 | 2011-03-15 | Implanted intelligent blood pressure regulating device |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN202061251U (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102671295A (en) * | 2011-03-15 | 2012-09-19 | 卢才义 | Implanted intelligent blood pressure adjusting device |
| CN106725399A (en) * | 2016-12-29 | 2017-05-31 | 深圳先进技术研究院 | A kind of light regulates and controls animal blood pressure real-time monitoring system |
-
2011
- 2011-03-15 CN CN2011200661858U patent/CN202061251U/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102671295A (en) * | 2011-03-15 | 2012-09-19 | 卢才义 | Implanted intelligent blood pressure adjusting device |
| CN106725399A (en) * | 2016-12-29 | 2017-05-31 | 深圳先进技术研究院 | A kind of light regulates and controls animal blood pressure real-time monitoring system |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11202908B2 (en) | Selective termination of stimulation to deliver post-stimulation therapeutic effect | |
| US8571654B2 (en) | Vagus nerve neurostimulator with multiple patient-selectable modes for treating chronic cardiac dysfunction | |
| ES2673959T3 (en) | Implantable device to provide electrical stimulation of cervical vagus nerves for the treatment of chronic cardiac dysfunction with limited adjustment | |
| ES2724453T3 (en) | Computer-implemented system to select profiles of electrical stimulation therapy of cervical vagus nerves for chronic cardiac dysfunction treatment | |
| US20160101289A1 (en) | Systems and methods for delivering vagal therapy | |
| CN102159279B (en) | Systems for regulation of blood pressure and heart rate | |
| US9031669B2 (en) | System for transvascularly stimulating autonomic targets | |
| US20210196963A1 (en) | Medical device recharging based on patient activity | |
| CN104349815B (en) | Device for adjusting blood pressure and heart rate | |
| US8755892B2 (en) | Systems for stimulating neural targets | |
| US9403007B2 (en) | Systems and methods to reduce syncope risk during neural stimulation therapy | |
| US8700174B2 (en) | Recharge coupling efficiency for patient posture state | |
| US20090018607A1 (en) | Methods and devices for controlling battery life in an implantable pulse generator | |
| US20130165994A1 (en) | Maintaining stimulation therapy efficacy | |
| JPH08229141A (en) | Cranial nerve stimulating medical treatment using nerve cybernetic type organism acting equipment | |
| CN102626538A (en) | Sleep detection-based integrated closed loop deep brain stimulator | |
| CN103785105B (en) | A kind of patient controller, implantable nerve stimulating system and feedback regulation method | |
| CN201453834U (en) | Therapeutic instrument for curing computer disease through transcranial magnetic stimulation | |
| CN111481830A (en) | Closed-loop electrical nerve stimulation system and method for setting parameters of closed-loop electrical nerve stimulation | |
| CN106075727A (en) | A kind of online diagnosis and therapy system based on nervus auricularis vagi stimulation instrument | |
| CN101244315A (en) | Microelectron hypertension instrument for carotid sinus | |
| CN101537228A (en) | Transcranial magnetic therapeutic instrument for computer diseases | |
| CN202061251U (en) | Implanted intelligent blood pressure regulating device | |
| ES2899684T3 (en) | Subthreshold direct current (DC) nerve conduction block after suprathreshold priming | |
| CN102671295A (en) | Implanted intelligent blood pressure adjusting device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: CHINESE PLA GENERAL HOSPITAL Free format text: FORMER OWNER: LU CAIYI Effective date: 20120903 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20120903 Address after: 100853 Fuxing Road, Beijing, Haidian District, No. 28 Patentee after: General Hospital of Chinese PLA Address before: 100853 No. 204, West Tower, 28 Fuxing Road, Beijing, Haidian District Patentee before: Lu Caiyi |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111207 Termination date: 20130315 |